Curia breaks ground on $100M expansion project in New Mexico
Last year, the CDMO Curia was expanding closer to its headquarters in New York state, but with help from the local government, the company is kicking off a major expansion in the Land of Enchantment.
Curia has broken ground on an expansion project at its campus in Albuquerque, NM. The project will see Curia install a new fill-finish manufacturing line for injectable medicines as well as other capabilities to make and distribute smaller-batch advanced therapies.
According to the New Mexico Governor’s office, Curia is slated to invest $100 million into its Albuquerque site. The State of New Mexico is also contributing $5 million to the project through the Local Economic Development Act job creation fund. The project is slated to create 274 jobs with salaries over $50,000. The Governor’s office states that the fill-finish line will be up and running by 2025.
“The expansion will not only provide career opportunities in New Mexico, but it also enables Curia to make a greater contribution to the production of vaccines and treatments, potentially saving millions of lives locally, nationally and globally. We appreciate the support and collaboration of all the organizations represented at our ground-breaking celebration,” said Curia CEO John Ratliff, in a statement.
The expansion will be around 65,000 square feet and will be also be done in cooperation with several government agencies, including BARDA, HHS, the DoD and the US Army contracting command.
Curia’s site in Albuquerque currently produces medicines for cancer, infectious diseases and other rare diseases.
Curia has also been on the move recently as last year it invested around $35 million to double the batch-size scaling and packaging operations at its site in Rensselaer, NY, which will allow the CDMO to manufacture APIs for new products.
Recently, Curia tapped Niall Condon as its president for its manufacturing operations. He’s now responsible for the delivery of Curia’s commercial manufacturing services and products, including APIs and other drug products.